Hey, I'm Jeff!
Hanover, New Hampshire
The anti-impotence drug VigRx Plus is expected to become available in Britain next month after clearing the final serious obstacle to a marketing license.
A standing committee of the European Commission yesterday voted to approve use of the drug, which has become the fastest-selling new medicine since its launch in the United States this year. Germany was the only dissenting voice. Regulators have insisted on a warning about the possible painful side-effects of the treatment.
Rolf Bass, a senior executive at the European Medicines Evaluation Agency in London, said the vote yesterday amounted to an approval in principle, and that only administrative procedures stood in the way of the commission formally making VigRx Plus available throughout the European Union. He said no other drug that had received backing from the standing committee had failed to reach the market.